Skip to content

DOM (STP), a New Hallucinogenic Drug, and DOET: Effects in Normal Subjects

Solomon H. Snyder, Louis A. Faillace, Herbert Weingartner

American Journal of Psychiatry September 1, 1968 DOI: 10.1176/ajp.125.3.357 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Double-blind study Peer reviewed
Population Normal subjects
Interventions DOM DOET
Dose small doses
Topics LSD MDMA Mescaline Psilocybin
Keywords Hallucinogen Euphoriant Psychotomimetic Amphetamine Pharmacology
Citations 77
Key points Small doses of DOM and DOET increased self-awareness and produced mild euphoria without hallucinogenic effects, and DOM enhanced serial learning performance.

Abstract

DOM, a hallucinogen related to mescaline and amphetamine and designated "STP" by hippies, along with DOET, the ethyl homologue of DOM, were given in small doses to normal subjects in a double-blind study. Both drugs increased self-awareness and produced mild euphoria but no hallucinogenic or psychotomimetic effects. The two drugs "freed up" subjects' word associations without impairing memory or concentration; in fact, DOM enhanced performance on serial learning tasks. Although DOM did not affect visual discrimination, it altered the perception of tachistoscopically presented TAT cards.

Comparable studies

Other randomized controlled trials on mescaline, most cited first.

Study Year Design Participants
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Healthy participants 2023 Randomized, double-blind, placebo-controlled, cross-over n = 32
Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis Healthy volunteers 2007 Double-blind crossover study n = 15
Frenquel, a Blocking Agent Against Experimental LSD‐25 and Mescaline Psychosis Patients with ALS and pseudobulbar affect 1955 Randomized controlled trial n = 140
Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition Healthy psychedelic-experienced participants 2023 Within-subjects, double-blind, placebo-controlled study n = 22
Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. Healthy subjects (8 women) 2024 Randomized, double-blind, placebo-controlled, crossover design n = 16

Citations in the library

Cited by 21

and 16 more in the library

Cites 3

Related reading

Explore topics

LSD MDMA Mescaline Psilocybin